UB Paderborn / Katalog / Suche / in CDI

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease

Journal of lipid research, 2018-09, Vol.59 (9), p.1640-1648

2018

Link zum Volltext

Verfügbarkeit prüfen

Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions

Pharmaceutical research, 2016-03, Vol.33 (3), p.751-762

2016

Link zum Volltext

Verfügbarkeit prüfen

Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology

Toxicological sciences, 2018-09, Vol.165 (1), p.50-60

2018

Link zum Volltext

Verfügbarkeit prüfen

Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients

Breast cancer research and treatment, 2016-04, Vol.156 (2), p.331-341

2016

Link zum Volltext

Verfügbarkeit prüfen

Understanding polyspecificity within the substrate‐binding cavity of the human multidrug resistance P‐glycoprotein

The FEBS journal, 2014-02, Vol.281 (3), p.673-682

2014

Link zum Volltext

Verfügbarkeit prüfen

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

Investigational new drugs, 2020-12, Vol.38 (6), p.1796-1806

2020

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

BMC cancer, 2011-11, Vol.11 (1), p.478-478, Article 478

2011

Link zum Volltext

Verfügbarkeit prüfen

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.319-327

2018

Link zum Volltext

Verfügbarkeit prüfen

Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group–174 Phase III Trial

International journal of gynecological cancer, 2016-01, Vol.26 (1), p.208-215

2016

Link zum Volltext

Verfügbarkeit prüfen

Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphoma

British journal of clinical pharmacology, 2012-04, Vol.73 (4), p.597-605

2012

Link zum Volltext

Verfügbarkeit prüfen

Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development

Gynecologic oncology, 2014-06, Vol.133 (3), p.460-466

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparing probabilistic and descriptive analyses of time–dose–toxicity relationship for determining no-observed-adverse-effect level in drug development

Toxicology and applied pharmacology, 2015-10, Vol.288 (2), p.240-248

2015

Link zum Volltext

Verfügbarkeit prüfen

Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation

Cancer chemotherapy and pharmacology, 2012-02, Vol.69 (2), p.447-455

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic interactions in mice between irinotecan and MBL‐II‐141, an ABCG2 inhibitor

Biopharmaceutics & drug disposition, 2017-07, Vol.38 (5), p.351-362

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of a drug–disease simulation model for rituximab in follicular non‐Hodgkin's lymphoma

British journal of clinical pharmacology, 2009-10, Vol.68 (4), p.561-573

2009

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy

The Prostate, 2009-09, Vol.69 (12), p.1325-1333

2009

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetically Based Estimation of Patient Compliance with Oral Anticancer Chemotherapies: In Silico Evaluation

Clinical pharmacokinetics, 2009-01, Vol.48 (6), p.359-369

2009

Link zum Volltext

Verfügbarkeit prüfen

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

Journal of pharmacokinetics and pharmacodynamics, 2013-02, Vol.40 (1), p.1-10

2013

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations

Advances in therapy, 2021-10, Vol.38 (10), p.5317-5332

2021

Link zum Volltext

Verfügbarkeit prüfen

Solid oral forms availability in children: a cost saving investigation

British journal of clinical pharmacology, 2014-11, Vol.78 (5), p.1080-1089

2014

Link zum Volltext

Verfügbarkeit prüfen

Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children

The AAPS journal, 2015-09, Vol.17 (5), p.1157-1167

2015

Link zum Volltext

Verfügbarkeit prüfen

A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

The AAPS journal, 2012-06, Vol.14 (2), p.155-163

2012

Link zum Volltext

Verfügbarkeit prüfen

Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS)

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.287-297

2014

Link zum Volltext

Verfügbarkeit prüfen

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.939-948

2015

Link zum Volltext

Verfügbarkeit prüfen

Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials

Critical reviews in oncology/hematology, 2015-05, Vol.94 (2), p.189-200

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease

Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions

Time-to-Event Modeling of Left- or Right-Censored Toxicity Data in Nonclinical Drug Toxicology

Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients

Understanding polyspecificity within the substrate‐binding cavity of the human multidrug resistance P‐glycoprotein

Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients

Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group–174 Phase III Trial

Model‐based design of rituximab dosage optimization in follicular non‐Hodgkin's lymphoma

Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development

Comparing probabilistic and descriptive analyses of time–dose–toxicity relationship for determining no-observed-adverse-effect level in drug development

Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation

Pharmacokinetic interactions in mice between irinotecan and MBL‐II‐141, an ABCG2 inhibitor

Development of a drug–disease simulation model for rituximab in follicular non‐Hodgkin's lymphoma

Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy

Pharmacokinetically Based Estimation of Patient Compliance with Oral Anticancer Chemotherapies: In Silico Evaluation

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations

Solid oral forms availability in children: a cost saving investigation

Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children

A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS)

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)

Concomitant drugs with low risks of drug–drug interactions for use in oncology clinical trials

Suchergebnisse filtern